The motion schedules a public hearing for the Board of Supervisors to discuss a proposed settlement related to a lawsuit against various opioid manufacturers and distributors. It also includes a closed session for the Board to consult with the City Attorney about the ongoing litigation.
Motion scheduling the Board of Supervisors to sit as a Committee of the Whole at the meeting on July 19, 2022, at 3:00 p.m. to hold a public hearing to consider the proposed ordinance (File No. 220819) endorsing partial settlement of the lawsuit filed on behalf of the City and County of San Francisco and the People of the State of California against manufacturers and distributors of prescription opioids, entitled The City and County of San Francisco and the People of the State of California v. Purdue Pharma L.P., Richard S. Sackler, Jonathan D. Sackler, Mortimer D.A. Sackler, Kathe A. Sackler, Ilene Sackler Lefcourt, Beverly Sackler, Theresa Sackler, David A. Sackler, Trust for the Benefit of Members of the Raymond Sackler Family, Rhodes Pharmaceuticals L.P., Cephalon, Inc., Teva Pharmaceutical Industries Ltd., Teva Pharmaceuticals USA, Inc., Endo International Plc, Endo Health Solutions Inc., Endo Pharmaceuticals Inc., Janssen Pharmaceuticals, Inc., Insys Therapeutics, Inc., Mallinckrodt Plc, Mallinckrodt LLC, Allergan Plc F/K/A Actavis Plc, Watson Pharmaceuticals, Inc. N/K/A Actavis, Inc., Watson Laboratories, Inc., Actavis LLC, Actavis Pharma, Inc. F/K/A/ Watson Pharma, Inc., AmerisourceBergen Corporation, Cardinal Health, Inc., and McKesson Corporation; and scheduling a closed session of the Board of Supervisors at the same meeting for the purpose of conferring with, or receiving advice from, the City Attorney regarding that existing litigation in which the City is a plaintiff, pursuant to California Government Code, Section 54956.9(a), and San Francisco Administrative Code, Section 67.10(d)(1).
How it got here
The hearing is set for July 19, 2022, to discuss ongoing litigation where San Francisco is suing multiple pharmaceutical companies over issues related to opioid distribution. This public meeting will allow residents to learn more about the case and its implications for the city.
This legislation allows the San Francisco Board of Supervisors to hold a closed session to discuss legal strategies with the City Attorney regarding ongoing litigation against several pharmaceutical companies related to the opioid crisis. The session is scheduled for July 19, 2022, in accordance with state and local laws.
The ordinance authorizes a $10 million settlement with Endo Health Solutions and related companies for their role in misleadingly marketing opioids and contributing to the opioid crisis in San Francisco. The settlement includes an immediate payment of $5 million, followed by $5 million paid in ten annual installments.
The ordinance authorizes a $10 million settlement with Endo Health Solutions and related companies for their role in misleadingly marketing opioids and contributing to the opioid crisis in San Francisco. The settlement includes an immediate payment of $5 million, followed by $5 million paid in ten annual installments.
The hearing is set for July 19, 2022, to discuss ongoing litigation where San Francisco is suing multiple pharmaceutical companies over issues related to opioid distribution. This public meeting will allow residents to learn more about the case and its implications for the city.
This legislation allows the San Francisco Board of Supervisors to hold a closed session to discuss legal strategies with the City Attorney regarding ongoing litigation against several pharmaceutical companies related to the opioid crisis. The session is scheduled for July 19, 2022, in accordance with state and local laws.
